Literature DB >> 2611484

Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase.

T Asano1, T Suzuki, M Tsuchiya, S Satoh, I Ikegaki, M Shibuya, Y Suzuki, H Hidaka.   

Abstract

The in vitro and in vivo vasorelaxant effects of HA1077, 1-(5-isoquinolinesulphonyl)-homopiperazine HCl, a novel vasodilator were examined. The inhibitory effects of HA1077 on contractile responses to various agonists were examined on strips of rabbit aorta. The concentration-response curves to 5-hydroxytryptamine, prostaglandin F2alpha, histamine, angiotensin II, noradrenaline and dopamine were concentration-dependently shifted to the right in the presence of HA1077 (0.3-3.0 microM). The in vivo vasodilator effects of HA1077 were examined in the constant-pressure autoperfused coronary vascular bed of dogs. Intra-coronary administration of HA1077 (3-30 micrograms per dog) dose-dependently increased coronary blood flow (CBF), with no effect on mean blood pressure (MBP) or heart rate (HR). Intra-coronary infusion of atropine, propranolol or diphenhydramine did not modify the in vivo coronary vasodilator response to HA1077. To determine the flow profile for HA1077 in dogs, blood flow in four vascular beds was measured, by use of noncannulating electromagnetic flow probes. HA1077 (0.01-0.3 mg kg-1, i.v.) dose-dependently decreased MBP and increased vertebral blood flow (VBF), CBF, renal blood flow (RBF) and femoral blood flow (FBF). A haemodynamic analysis showed that continuous i.v. infusion of HA1077 (0.01 and 0.033 mg kg-1min-1) dose-dependently decreased peripheral vascular resistance and increased cardiac output. There were no significant changes in right atrial pressure, dP/dt or ventricular minute work. The effects of HA1077 on various enzymes considered to be related to the regulation of smooth muscle contraction were examined. HA1077 had little effect on cyclic nucleotide phosphodiesterases, yet it potently inhibited protein kinases such as cyclic nucleotide dependent protein kinases and Ca2+/calmodulin dependent myosin light chain kinase. The present study demonstrates that HA1077 is a novel type of arterial vasodilator.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2611484      PMCID: PMC1854800          DOI: 10.1111/j.1476-5381.1989.tb12652.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  A NEW PROTEIN COMPONENT PARTICIPATING IN THE SUPERPRECIPITATION OF MYOSIN B.

Authors:  S EBASHI; F EBASHI
Journal:  J Biochem       Date:  1964-06       Impact factor: 3.387

2.  Activation of myosin light chain kinase by trypsin.

Authors:  T Tanaka; M Naka; H Hidaka
Journal:  Biochem Biophys Res Commun       Date:  1980-01-15       Impact factor: 3.575

Review 3.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

4.  A new assay of cyclic nucleotide phosphodiesterase; its application to human serum.

Authors:  H Hidaka; M Shibuya
Journal:  Biochem Med       Date:  1974-08

5.  Purification and characterization of cyclic GMP-dependent protein kinases.

Authors:  J F Kuo; P Greengard
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

6.  Preparation of homogeneous cyclic AMP-dependent protein kinase(s) and its subunits from rabbit skeletal muscle.

Authors:  J A Beavo; P J Bechtel; E G Krebs
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

7.  Cyclic nucleotide-dependent protein kinases. IV. Widespread occurrence of adenosine 3',5'-monophosphate-dependent protein kinase in various tissues and phyla of the animal kingdom.

Authors:  J F Kuo; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1969-12       Impact factor: 11.205

Review 8.  Regulation and kinetics of the actin-myosin-ATP interaction.

Authors:  R S Adelstein; E Eisenberg
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

9.  Cerebral arterial spasm: part 10. Reversal of acute and chronic spasm in dogs with orally administered nifedipine.

Authors:  G S Allen; A L Bahr
Journal:  Neurosurgery       Date:  1979-01       Impact factor: 4.654

10.  A novel vascular relaxing agent, N-(6--aminohexyl)-5-chloro-1-naphthalensulfonamide which affects vascular smooth muscle actomyosin.

Authors:  H Hidaka; M Asano; S Iwadare; I Matsumoto; T Totsuka; N Aoki
Journal:  J Pharmacol Exp Ther       Date:  1978-10       Impact factor: 4.030

View more
  23 in total

1.  Inhibition of Rho-associated kinase blocks agonist-induced Ca2+ sensitization of myosin phosphorylation and force in guinea-pig ileum.

Authors:  K Swärd; K Dreja; M Susnjar; P Hellstrand; D J Hartshorne; M P Walsh
Journal:  J Physiol       Date:  2000-01-01       Impact factor: 5.182

2.  A versatile synthesis of substituted isoquinolines.

Authors:  Chong Si; Andrew G Myers
Journal:  Angew Chem Int Ed Engl       Date:  2011-09-09       Impact factor: 15.336

3.  Rho-kinase inhibitors prevent agonist-induced vasospasm in human internal mammary artery.

Authors:  T J Batchelor; J R Sadaba; A Ishola; P Pacaud; C M Munsch; D J Beech
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 4.  The Rho GTPase signalling pathway in urothelial carcinoma.

Authors:  Solomon L Woldu; Ryan C Hutchinson; Laura-Maria Krabbe; Oner Sanli; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

5.  Attenuation of pressure-induced myogenic contraction and tyrosine phosphorylation by fasudil, a cerebral vasodilator, in rat cerebral artery.

Authors:  N Masumoto; Y Tanabe; M Saito; K Nakayama
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 6.  Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders.

Authors:  F V Brozovich; C J Nicholson; C V Degen; Yuan Z Gao; M Aggarwal; K G Morgan
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

7.  Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina.

Authors:  T Utsunomiya; S Satoh; I Ikegaki; Y Toshima; T Asano; H Shimokawa
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

8.  Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils.

Authors:  S Satoh; I Ikegaki; Y Suzuki; T Asano; M Shibuya; H Hidaka
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

9.  {alpha}MSH and Cyclic AMP elevating agents control melanosome pH through a protein kinase A-independent mechanism.

Authors:  Yann Cheli; Flavie Luciani; Mehdi Khaled; Laurent Beuret; Karine Bille; Pierre Gounon; Jean-Paul Ortonne; Corine Bertolotto; Robert Ballotti
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

10.  The effects of HA1077, a novel protein kinase inhibitor, on reductions of cerebral blood flow and glucose metabolism following acute and/or chronic bilateral carotid artery ligation in Wistar rats.

Authors:  M Tsuchiya; K Sako; Y Yonemasu; T Asano
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.